Aurora Cannabis Inc (ACB.TO) is set to report its earnings on June 11, 2026, with analysts estimating a loss of CA$0.50 per share. As the company navigates a challenging market, all eyes will be on its performance amidst Europe's booming cannabis sector.
Aurora Cannabis Inc is scheduled to release its earnings report before the market opens on June 11, 2026. The company is expected to report an earnings per share (EPS) of -CA$0.50, continuing its trend of losses as it seeks to stabilize amidst a shifting cannabis landscape. With a market cap of CA$286.76 million and a profit margin of -22.51%, investors are keen to see if there are signs of recovery or further challenges ahead.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Aurora Cannabis Inc
ACB.TO
ACB.TO
Aurora Cannabis Inc
WealthAwesomeMarket cap
$237.24M
52W high
$9.33
52W low
$3.74
1W change
-5.62%
Beta
1.35
Analyst Price Targets
Based on analyst covering ACB
Wall Street analysts forecast ACB stock price to rise 51.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$5.84
+51.3% Upside
Current Price
C$3.86
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ACB's historical volatility
30-Day Vol
41.0%
Annualized
90-Day Vol
48.9%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$3.23
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$3.64 | C$3.16 โ C$4.19 |
| 60 trading days | C$3.43 | C$2.81 โ C$4.18 |
| 90 trading days | C$3.23 | C$2.53 โ C$4.12 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Long-term investors should watch for any indications of strategic pivots or growth opportunities in the evolving cannabis market.
The Stakes for Aurora's Earnings: A CA$0.50 Loss Expected
With an EPS estimate of -CA$0.50, Aurora Cannabis Inc continues to grapple with significant losses. This figure underscores the ongoing challenges the company faces, especially as it competes in a rapidly evolving global cannabis market. Investors will be looking for any signs of improvement or strategic direction in the upcoming report.
Bull case
- Market Potential: The European cannabis market is growing quickly, and Aurora could benefit from rising international demand.
- Strategic Adjustments: Positive changes in how the company operates or manages costs could indicate a turnaround.
- Investor Interest: As institutional investors seek compliant operators, Aurora's position might attract new capital.
Bear case
- Continued Losses: If the report shows a loss that meets or exceeds expectations, it could raise more concerns about the company's profitability.
- Market Competition: Increased competition in the cannabis sector, especially from European players, may pressure Aurora's market share.
- Regulatory Risks: Ongoing regulatory changes could affect Aurora's ability to operate effectively in various markets.
Aurora Cannabis Inc: Company Overview
Aurora Cannabis Inc is a leading player in the cannabis industry, focusing on the production and distribution of medical and recreational cannabis products. With operations spanning across Canada and emerging markets in Europe, Aurora is positioning itself to capitalize on the growing global demand for cannabis.
What the Upcoming Earnings Report Could Reveal
Analysts are projecting a continued loss for Aurora, with an EPS estimate of -CA$0.50. Investors will be keen to see if the company can provide insights into its operational strategies and any potential recovery plans in light of the expanding European market.
Key Market Context for Aurora's Earnings
The cannabis market is witnessing significant growth, particularly in Europe, where demand for medical cannabis is increasing. As more countries establish regulatory frameworks, Aurora's ability to adapt and thrive in this evolving landscape will be crucial for its future performance.
Advertisement
